

## AMENDMENTS TO THE CLAIMS

### **Listing of Claims:**

Claims 1-31 (canceled)

Claim 32 (currently amended): A combination which comprises (a) at least one antineoplastic agent selected from the group consisting of ~~topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, protein kinase C inhibitors, anti-angiogenic compounds, gonadotropin-releasing hormone agonists, anti-androgens, histone deacetylase inhibitors, and S-adenosylmethionine decarboxylase inhibitors~~ and (b) an epothilone which is epothilone B, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

Claims 33-40 (cancelled).

Claim 41 (currently amended): Combination according to claim 32 ~~38~~ which is a combined preparation.

Claim 42 (cancelled)

Claim 43 (currently amended): Method of treating a warm-blooded animal having a proliferative disease comprising administering to the animal a combination according to claim 32 ~~20~~ in a quantity which is jointly therapeutically effective against a proliferative disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 44 (currently amended): A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a proliferative disease of a combination according to claim 32 ~~20~~ and at least one pharmaceutically acceptable carrier.

Claim 45 (currently amended): A combination according to claim 32 ~~20~~ for use in the treatment of a proliferative disease.

Claims 46-50 (cancelled)